
==== Front
Arch Virol
Arch. Virol
Archives of Virology
0304-8608 1432-8798 Springer-Verlag Vienna 

16508703
734
10.1007/s00705-006-0734-y
Article
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31
Fleury M. J. J. 1 Touzé A. 1 Alvarez E. 1 Carpentier G. 1 Clavel C. 2 Vautherot J.-F. 3 Coursaget P. 1  grid.12366.300000000121826141INSERM U618, Université François Rabelais, Tours, France 
 grid.414215.70000000406394792Hôpital Maison Blanche, Laboratoire Pol Bouin, Reims, France 
 INRA UR086 BASE, Nouzilly, France 
3 3 2006 
2006 
151 8 1511 1523
25 7 2005 25 1 2006 © Springer-Verlag 2006This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Summary.
The majority of the neutralizing epitopes of papillomaviruses (PV) are conformation-specific and have not been fully characterised. Studies have, to date, been limited to a few HPV types only. We analysed the epitopes on the major capsid protein (L1) of Human papillomavirus (HPV) type 31 using monoclonal antibodies (MAbs) generated against HPV-31 virus-like particles (VLPs). The type-specific MAbs against HPV-31 were all found to be neutralizing and recognized conformation-dependent epitopes. Two other MAbs directed against a conformational epitope were found to be cross-reactive with other HPV types, and one of them was found to be cross-neutralizing. Cross-reactive antibodies were further investigated using wild-type HPV-16 L1 VLPs and two mutants. The results obtained suggested the existence of a cross-neutralizing conformational epitope at the N-terminal part of the FG loop of the major capsid protein, and the other four cross-reactive MAbs recognized epitopes also located at the N-terminal part of the FG loop.

Keywords
Conformational EpitopeMajor Capsid ProteinLinear EpitopeViruslike ParticleMinor Capsid Proteinissue-copyright-statement© Springer-Verlag 2006
==== Refs
References
Bousarghin L Touzé A Combita AL El Mehdaoui S Sizaret PY Bravo MM Coursaget P  Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions
J Clin Microbiol 2002 40 926 932
10.1128/JCM.40.3.926-932.2002 11880418 
Breitburd F Kirnbauer R Hubbert NL Nonnenmacher B Trin-Dinh-Desmarquet C Orth G Schiller JT Lowy DR  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
J Virol 1995 69 3959 3963
7745754 
Brown DR Fife KH Wheeler CM Koutsky LA Lupinacci LM Railkar R Suhr G Barr E Dicello A Li W Smith JF Tadesse A Jansen KU  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine
Vaccine 2004 22 2936 2942
10.1016/j.vaccine.2003.11.059 15246630 
Carter JJ Wipf GC Benki SF Christensen ND Galloway DA  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1
J Virol 2003 77 11625 11632
10.1128/JVI.77.21.11625-11632.2003 14557648 
Cason J Patel D Naylor J Lunney D Shepherd PS Best JM McCance DJ  Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes
J Gen Virol 1989 70 2973 2987
2479716 
Christensen ND Kreider JW Cladel NM Patrick SD Welsh PA  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11
J Virol 1990 64 5678 5681
2170694 
Christensen ND Kirnbauer R Schiller JT Ghim SJ Schlegel R Jenson AB Kreider JW  Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
Virology 1994a 205 329 335
10.1006/viro.1994.1649 7526536 
Christensen ND Hopfl R DiAngelo SL Cladel NM Patrick SD Welsh PA Budgeon LR Reed CA Kreider JW  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies
J Gen Virol 1994b 75 2271 2276
7521393 
Christensen ND Dillner J Eklund C Carter JJ Wipf GC Reed CA Cladel NM Galloway DA  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
Virology 1996 223 174 184
10.1006/viro.1996.0466 8806551 
Christensen ND Reed CA Cladel NM Hall K Leiserowitz GS  Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6
Virology 1996 224 477 486
10.1006/viro.1996.0554 8874508 
Christensen ND Cladel NM Reed CA Budgeon LR Embers ME Skulsky DM McClements WL Ludmerer SW Jansen KU  Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types
Virology 2001 291 324 334
10.1006/viro.2001.1220 11878901 
Combita AL Touzé A Bousarghin L Christensen ND Coursaget P  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomavirus
J Virol 2002 76 6480 6486
10.1128/JVI.76.13.6480-6486.2002 12050360 
Combita AL Bravo MM Touzé A Orozco O Coursaget P  Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer
Int J Cancer 2002 97 796 803
10.1002/ijc.10153 11857357 
Giroglou T Sapp M Lane C Fligge C Christensen ND Streek RE Sapp M  Immunological analyses of human papillomavirus capsids
Vaccine 2001 19 1783 1793
10.1016/S0264-410X(00)00370-4 11166904 
Goldborough MD DiSelvestre D Temple GF Lorincz AT  Nucleotide sequence of human papillomavirus type 31: A cervical neoplasia associated virus
Virology 1989 171 306 311
10.1016/0042-6822(89)90545-X 2545036 
Harper DM Franco EL Wheeler C Ferris DG Jenkins D Schuind A Zahaf T Innis B Naud P De Carvalho NS Roteli-Martins CM Teixeira J Blatter MM Korn AP Quint W Dubin G GlaxoSmithKline HPV Vaccine Study Group  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Lancet 2004 364 1757 1765
10.1016/S0140-6736(04)17398-4 15541448 
Harro CD Pang YY Roden RB Hildesheim A Wang Z Reynolds MJ Mast TC Robinson R Murphy BR Karron RA Dillner J Schiller JT Lowy DR  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
J Natl Cancer Inst 2001 93 284 292
10.1093/jnci/93.4.284 11181775 
Heino P Skyldberg B Lehtinen M Rantala I Hagmar B Kreider JW Kirnbauer R Dillner J  Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes
J Gen Virol 1995 76 1141 1153
7537325 
Kawana K Yoshikawa H Taketani Y Yoshiike K Kanda T  Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6
J Virol 1999 73 6188 6190
10364381 
Kirnbauer R Taub J Greenstone H Roden R Durst M Gissmann L Lowy DR Schiller JT  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into viruslike particles
J Virol 1993 67 6929 6936
8230414 
Kirnbauer R Chandrachud LM O’Neil BW Wagner ER Grindlay GJ Armstrong A McGarvie GM Schiller JT Lowy DR Campo MS  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
Virology 1996 219 37 44
10.1006/viro.1996.0220 8623552 
Koutsky LA Ault KA Wheeler CM Brown DR Barr E Alvarez FB Chiacchierini LM Jansen KU  A controlled trial of a human papillomavirus type 16 vaccine
N Engl J Med 2002 347 1645 1651
10.1056/NEJMoa020586 12444178 
Kulski JK Sadleir JW Kelsall SR Cicchini MS Shellam G Peng SW Qi YM Galloway DA Zhou J Frazer IH  Type specific and genotype cross reactive B 20 epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies
Virology 1998 243 275 282
10.1006/viro.1997.9011 9568027 
Ludmerer SW Benincasa D Mark GE 3rd Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11
J Virol 1996 70 4791 4794
8676509 
Ludmerer SW Benincasa D Mark GE 3rdChristensen ND  A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope
J Virol 1997 71 3834 3839
9094659 
Ludmerer SW McClements WL Wang XM Ling JC Jansen KU Christensen ND  HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain
Virology 2000 266 237 245
10.1006/viro.1999.0083 10639310 
McClements WL Wang XM Ling JC Skulsky DM Christensen ND Jansen KU Ludmerer SW  A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1
Virology 2001 289 262 268
10.1006/viro.2001.1146 11689049 
Munoz N Bosch FX de Sanjose S Herrero R Castellsague X Shah KV Snijders PJ Meijer CJ  Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Engl J Med 2003 348 518 527
10.1056/NEJMoa021641 12571259 
Roden RB Weissinger EM Henderson DW Booy F Kirnbauer R Mushinski JF Lowy DR Schiller JT  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
J Virol 1994 68 7570 7574
7523700 
Roden RB Armstrong A Haderer P Christensen ND Hubbert NL Lowy DR Schiller JT Kirnbauer R  Characterization of a human papillomavirus type 16 variant dependent neutralizing epitope
J Virol 1997 71 6247 6252
9223527 
Roden RB Yutzy WH 4thFallon R Inglis S Lowy DR Schiller JT  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
Virology 2000 270 254 257
10.1006/viro.2000.0272 10792983 
Sadeyen JR Tourne S Shkreli M Sizaret PY Coursaget P  Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their immunogenicity and delineates a conformational neutralizing epitope
Virology 2003 309 32 40
10.1016/S0042-6822(02)00134-4 12726724 
Slupetzky K Shafti-Keramat S Lenz P Brandt S Grassauer A Sara M Kirnbauer R  Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops
J Gen Virol 2001 82 2799 2804
11602792 
Suzich JA Ghim SJ Palmer-Hill FJ White WI Tamura JK Bell JA Newsome JA Jenson AB Schlegel R  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
Proc Natl Acad Sci USA 1995 92 11553 11557
10.1073/pnas.92.25.11553 8524802 
Thouvenin E Laurent S Madelaine MF Rasschaert D Vautherot JF Hewat EA  Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge
J Mol Biol 1997 270 238 246
10.1006/jmbi.1997.1095 9236125 
Touzé A El Mehdaoui S Sizaret PY Mougin C Munoz N Coursaget P  The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system
J Clin Microbiol 1998 36 2046 2051
9650960 
Vautherot JF Madelaine MF Boireau P Laporte J  Bovine coronavirus peplomer glycoproteins: detail antigenic analyses of S1, S2 and HE
J Gen Virol 1992 73 1725 1737
1378480 
Viscidi RP Snyder B Cu-Uvin S Hogan JW Clayman B Klein RS Sobel J Shah KV  Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women
Cancer Epidemiol Biomarkers Prev 2005 14 283 288
15668510 
Volpers C Sapp M Snijders PJ Walboomers JM Streeck RE  Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2
J Gen Virol 1995 76 2661 2667
10.1099/0022-1317-76-11-2661 7595373 
Walboomers JM Jacobs MV Manos MM Bosch FX Kummer JA Shah KV Snijders PJ Peto J Meijer CJ Munoz N  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
J Pathol 1999 189 12 19
10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 
Wang XM Cook JC Lee JC Jansen KU Christensen ND Ludmerer SW McClements WL  Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes
J Gen Virol 2003 84 1493 1497
10.1099/vir.0.18872-0 12771418 
White WI Wilson SD Bonnez W Rose RC Koenig S Suzich JA  In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
J Virol 1998 72 959 964
9444988 
White WI Wilson SD Palmer-Hill FJ Woods RM Ghim SJ Hewitt LA Goldman DM Burke SJ Jenson AB Koenig S Suzich JA  Characterization of a major neutralizing epitope on human papillomavirus type 16 L1
J Virol 1999 73 4882 4889
10233949 
Yaegashi N Jenison SA Valentine JM Dunn M Taichman LB Baker DA Galloway DA  Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions
J Virol 1991 65 1578 1583
1847474 
Zhang LF Zhou J Chen S Cai LL Bao QY Zheng FY Lu JQ Padmanabha J Hengst K Malcolm K Frazer IH  HPV6b virus like particles are potent immunogens without adjuvant in man
Vaccine 2000 18 1051 1058
10.1016/S0264-410X(99)00351-5 10590325

